Support teaching, research, and patient care.
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Martina Steffen
650-498-7061
All fields are required. *
We were not able to send your contact info at this time.